Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort study
RAISE delivers personalized 6-, 12-, 18- and 24-month infection risk estimates using routinely available data, improving on the scope and relevance of earlier prediction tools. It enables risk-based treatment planning and preventive strategies, with potential for international adoption following external validation.
Authors
- É. Sbidian (ORCID: https://orcid.org/0000-0002-1267-5270)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Mounya Abboud
Institutions
- Conservatoire National des Arts et Métiers (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Est Créteil (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- CIC Rennes (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1093/rheumatology/keaf644
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00